Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats
rHuEPO plays a central role as chemicals for the treatment of many diseases. Due to its short half-life, the main aim for this pharmacokinetic study is to investigate a newly developed PEG-rHuEPO with large molecular weight in SD rats. After a single intramuscular administration of different doses o...
Saved in:
Main Authors: | Xiaohan Cao, Zhiyong Chen, Zhuoran Yu, Yonghong Ge, Xianyin Zeng |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Journal of Analytical Methods in Chemistry |
Online Access: | http://dx.doi.org/10.1155/2014/918686 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recombinant human erythropoietin, and myocardial and cerebral acute ischemia: implications for clinical use.
by: Rafael Alejandro Gómez Baute, et al.
Published: (2010-07-01) -
Clinical Recommendations for the Use of Recombinant Human Erythropoietin in Patients with Hepatitis C Virus Being Treated with Ribavirin
by: Morris Sherman, et al.
Published: (2006-01-01) -
Flanker Task-Elicited Event-Related Potential Sources Reflect Human Recombinant Erythropoietin Differential Effects on Parkinson’s Patients
by: Maria L. Bringas Vega, et al.
Published: (2020-01-01) -
Possible erythropoietin pharmacotherapeutic targets on painful diabetic neuropathy in rats
by: SAMUEL SUAREZ-MENDEZ, et al.
Published: (2025-02-01) -
Erythrocytes and Erythropoietin
by: Michael Föller, et al.
Published: (2011-01-01)